Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $47,771 - $56,430
-570 Reduced 6.6%
8,061 $704,000
Q4 2023

Feb 13, 2024

BUY
$76.22 - $98.51 $111,433 - $144,021
1,462 Added 20.39%
8,631 $832,000
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $42,194 - $46,862
-496 Reduced 6.47%
7,169 $634,000
Q2 2023

Aug 09, 2023

BUY
$86.68 - $100.3 $111,210 - $128,684
1,283 Added 20.1%
7,665 $664,000
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $65,805 - $87,952
-750 Reduced 10.52%
6,382 $620,000
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $32,776 - $43,995
405 Added 6.02%
7,132 $738,000
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $103,850 - $122,532
1,264 Added 23.14%
6,727 $570,000
Q2 2022

Aug 11, 2022

SELL
$71.48 - $86.85 $4,431 - $5,384
-62 Reduced 1.12%
5,463 $453,000
Q1 2022

May 12, 2022

BUY
$74.28 - $92.69 $113,648 - $141,815
1,530 Added 38.3%
5,525 $426,000
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $244,995 - $312,461
-3,416 Reduced 46.09%
3,995 $353,000
Q3 2021

Nov 16, 2021

BUY
$74.77 - $85.47 $63,479 - $72,564
849 Added 12.94%
7,411 $573,000
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $291,921 - $327,798
3,866 Added 143.4%
6,562 $548,000
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $201,472 - $244,500
2,696 New
2,696 $204,000
Q3 2020

Nov 13, 2020

SELL
$71.87 - $131.03 $140,793 - $256,687
-1,959 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $155,838 - $243,346
1,959 New
1,959 $242,000
Q4 2019

Feb 10, 2020

SELL
$64.27 - $86.37 $220,703 - $296,594
-3,434 Closed
0 $0
Q3 2019

Nov 06, 2019

BUY
$67.4 - $85.11 $1,887 - $2,383
28 Added 0.82%
3,434 $232,000
Q2 2019

Aug 12, 2019

BUY
$80.35 - $93.9 $273,672 - $319,823
3,406 New
3,406 $293,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Cetera Advisor Networks LLC Portfolio

Follow Cetera Advisor Networks LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Advisor Networks LLC with notifications on news.